Press Releases

2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

2004 Press Releases

Listed below are all of the QLT press releases available for the year you have selected.

December 21	Eligard® Gains Approvals in 24 European Countries	PDF version
December 15	FDA Approves Eligard® Six-Month Formulation for Prostate Cancer	PDF version
December 8	QLT Hosts 2004 Analyst & Investor Meeting and Webcast	PDF version
November 19	QLT and Atrix Laboratories Complete Merger	PDF version
October 21	QLT Announces Q3 Results for 2004	PDF version
October 14	QLT And Atrix Laboratories Joint Proxy Statement Cleared By SEC	PDF version
October 14	Visudyne® in Occult (VIO) Trial to Continue to its Conclusion at 24 Months	PDF version
August 30	QLT Reiterates Confidence in Visudyne's Potential	PDF version
July 22	QLT Announces Q2 Results for 2004	PDF version
July 20	QLT Announces Visudyne® Sales for Second Quarter of 2004	PDF version
July 13	QLT Inc. and Atrix Laboratories, Inc. Announce Early Termination of Hart-Scott-Rodino Waiting Period	PDF version
June 14	QLT Inc. and Atrix Laboratories Inc. Combine to Create Leading Profitable Biopharmaceutical Company	PDF version
June 2	QLT Collaborates With the National Eye Institute to Develop Preservative-Free Triamcinolone	PDF version
April 27	QLT Announces Q1 Results for 2004 and Updates Guidance	PDF version
April 23	QLT Announces Reimbursement for Visudyne® in Japan for Treatment of Age-Related Macular Degeneration	PDF version
April 22	QLT Announces Visudyne® Sales for First Quarter of 2004	PDF version
April 2	QLT Announces Securities Class Action Lawsuit Is Dismissed	PDF version
April 1	QLT Announces New Medicare Policy Takes Effect Expanding Reimbursement for Visudyne®	PDF version
March 29	QLT to Acquire Kinetek Pharmaceuticals Inc.	PDF version
March 16	QLT Announces Visudyne® to Receive Centers for Medicare and Medicaid Exception on Allowable Reimbursement Level	PDF version
February 11	QLT Reports 2003 Fourth Quarter and Full Year Earnings Per Share of $0.13 and $0.65 and Provides Guidance for 2004	PDF version
January 29	QLT and Novartis Announce Centers for Medicare and Medicaid Services Intend to Reimburse Visudyne® for Occult and Minimally Classic Lesions in AMD	PDF version
January 23	QLT Announces Effectiveness of its Registration Statement on Form S-3 for its August 2003 Private Placement of Convertible Notes	PDF version
January 22	QLT Announces Visudyne® Sales for Fourth Quarter and Fiscal Year 2003	PDF version
January 19	QLT Announces Discount to Physician Customers in Response to the Reduction in Medicare Reimbursement for Visudyne®	PDF version

Visudyne® is a registered trademark of Novartis AG

Vancouver Web Design by Graphically Speaking